Thiazolidinediones

THIAZOLES with two keto oxygens. Members are insulin-sensitizing agents which overcome INSULIN RESISTANCE by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma).

Also Known As:

Networked: 1363 relevant articles (109 outcomes, 161 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Staels, Bart: 11 articles (05/2012 - 05/2005)
2.	Scheen, A J: 11 articles (08/2007 - 03/2000)
3.	Singh, Sonal: 8 articles (12/2014 - 08/2007)
4.	Plutzky, Jorge: 8 articles (01/2007 - 01/2002)
5.	Sarafidis, Pantelis A: 7 articles (12/2011 - 01/2006)
6.	Dandona, Paresh: 7 articles (08/2010 - 12/2003)
7.	Fonseca, Vivian: 7 articles (09/2006 - 01/2003)
8.	Lasaridis, Anastasios N: 6 articles (12/2011 - 09/2004)
9.	Scheen, André J: 6 articles (09/2010 - 03/2002)
10.	Tsai, Yi-Wen: 5 articles (10/2014 - 01/2009)

Related Diseases

1.	Insulin Resistance 05/01/2003 - "The newest class, the thiazolidinediones (TZDs), should be a mainstay of treatment for most patients with type 2 diabetes, because these agents reduce insulin resistance as well as improve glycemic control. " 06/01/1995 - "Agents that reduce insulin resistance include the thiazolidinediones, which are very effective in animals. " 07/01/2003 - "In summary, with the thiazolidinediones, a novel concept for the treatment of insulin resistance and possibly preservation of beta-cell function is available that could become effective in the prevention of Type 2 diabetes. " 12/01/1996 - "Clinical studies in patients with type II diabetes, as well as other syndromes characterized by insulin resistance, have demonstrated that thiazolidinediones may represent a safe and effective new treatment. " 09/01/2001 - "The thiazolidinediones are a new class of drug that ameliorate insulin resistance, and we await to see if their use is associated with improved diabetes outcomes. "
2.	Type 2 Diabetes Mellitus (MODY) 06/01/2002 - "The glitazones: a new treatment for type 2 diabetes mellitus." 01/01/2000 - "Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus." 06/01/2007 - "Clinicians should become familiar with glitazones as they are experiencing a burgeoning use among patients with non-insulin-dependent diabetes mellitus and have demonstrated clinical efficacy in treating certain skin conditions." 07/01/2010 - "Whether thiazolidinediones should be used to treat patients with type 2 diabetes mellitus is controversial, as studies on the cardiovascular effects of these drugs have produced conflicting results. " 09/01/2006 - "Ongoing clinical trials are underway investigating the role of thiazolidinediones in the prevention of type 2 diabetes mellitus."
3.	Weight Gain 11/01/2011 - "Medication combinations that improve the efficacy of thiazolidinediones or ameliorate weight-gain side effects of therapy represent an attractive potential treatment for (NASH). " 03/01/2011 - "The reported improved glycemic control with thiazolidinediones use seems to be associated with an increase in weight with an estimated 2-3 kg weight gain suggesting that maybe thiazolidinediones are not safe for the clinical use. " 03/01/2011 - "Other authors reported that thiazolidinediones give an improvement in the glycemic without giving weight gain. " 12/01/2013 - "Here, using in-depth physiology studies, we investigate whether obese patients with T2DM are likely to benefit from thiazolidinediones, medications with a known adverse effect of weight gain. " 09/01/2007 - "The larger trials have shown that glitazones produce a weight gain of 4-5 kg over 3-4 years of treatment, and the weight gain cannot be explained by fluid retention. "
4.	Weight Loss (Weight Reduction) 12/01/2008 - "The weight of data point to greatest biochemical and histological benefit with weight-loss measures and thiazolidinediones, but further trials are needed to characterize the benefits and risks of the latter agents. " 04/01/2014 - "All patient subgroups had a mean weight loss irrespective of OAD continuation, apart from those continuing thiazolidinediones (+0·2 kg). " 01/01/2003 - "The weight loss observed was no different from that observed in 16 age- and gender-matched patients with type 2 diabetes not treated with thiazolidinediones (from 263 +/- 54 lbs (120 +/- 25 kg) to 239 +/- 52 lbs (109 +/- 24 kg); p < 0.01). " 01/01/2003 - "Is weight loss possible in patients treated with thiazolidinediones? " 01/01/2003 - "We conclude that a program of caloric restriction and behavior modification is effective in leading to weight loss in patients treated with thiazolidinediones. "
5.	Inflammation 01/01/2009 - "Data from animal and human studies supports the concept that thiazolidinediones exert several other beneficial metabolic and vascular effects, in addition to glycaemic control, including improvement in lipid profile, blood pressure lowering, redistribution of body fat away from the central compartment, anti-inflammatory effects such as reduction in hs-CRP and microalbuminuria as well as subclinical vascular inflammation, improvement in endothelial function. " 01/01/2012 - "Thiazolidinediones significantly improve ballooning degeneration, lobular inflammation, steatosis and combined necroinflammation in patients with NASH. " 01/01/2011 - "Through PPARγ stimulation, however, glitazones also affect other genes, encompassing inflammation, cell growth and differentiation, angiogenesis, which broads their therapeutic potential. " 01/01/2009 - "Glitazones improve endothelial function and reduce inflammation, but much less is known about their effect on thrombogenic factors. " 11/01/2007 - "Previous investigations suggested thiazolidinediones (TZDs) have the ability to suppress inflammation. "

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Metformin (Glucophage)
3.	PPAR gamma
4.	Glucose (Dextrose)
5.	Fibric Acids (Fibrates)
6.	Ligands
7.	pioglitazone (Actos)
8.	rosiglitazone (Avandia)
9.	troglitazone (Rezulin)
10.	Peroxisome Proliferator-Activated Receptors (PPAR)

Related Therapies and Procedures

1.	Caloric Restriction
2.	Stents
3.	Phototherapy (Light Therapy)
4.	Lasers (Laser)
5.	Highly Active Antiretroviral Therapy (HAART)